In terms of the mechanism, ISL can inhibit m6A modification and downregulate the expression level of IGF2BP3 in NSCLC cells, thus suppressing the proliferation, migration, and invasion of NSCLC cells (153). The gene discussed is IGF2BP3; the disease is non-small cell lung carcinoma.